Monitoring ARIA in Anti-Amyloid Therapy in Alzheimer's - Medscape
Oct 29, 2024 · Alzheimer's disease (AD) is the most common form of dementia worldwide. Past treatments have focused on managing symptoms, whereas recent advancements, including anti–amyloid-beta monoclonal ...
Phase 3 Izokibep Study in HS Produces Promising Results
Oct 8, 2024 · One third of the participants treated with the drug achieved at least a 75% reduction in the HS Clinical Response (HiSCR75) at 12 weeks, which was the primary endpoint in the trial ...
New Ideas on PsA Pathogenesis May Drive New Treatments
Jan 7, 2025 · In the context of PsA, Scher said, monocytes that express heightened inflammatory responses driven by metabolic and epigenetic reprogramming can become “trained” by triggers such as infections ...
Alcohol-Associated Liver Disease Is On the Rise: What to Know
Mar 11, 2024 · A Lille score of > 0.45 on days 4-7 of starting medical therapy defines a response to treatment. An online tool is available for the Lille score in AH. The major factor in its calculation is a ...
Inflammation Now the Key Target for Seborrheic Dermatitis
Jan 6, 2025 · Now that there is compelling evidence that seborrheic dermatitis is best characterized as an inflammatory disease, the use of topical antifungals, despite the efficacy they offer, should be placed ...
Axolotl Shows Promise in Unlocking Skin Regeneration Secrets
Dec 30, 2024 · The immune response, particularly the actions of macrophages and neutrophils, is also crucial in the early stages of regeneration, as these cells clear away dead tissue and kickstart the healing ...
Episode 1: Optimizing HER2-Positive Breast Cancer Therapy
Aug 20, 2024 · This scenario comes up, for example, in patients who, let's say, got induction therapy with THP for first-line treatment, maybe went into a complete response, and went on to dual HER2-directed ...
More Biologics May Be Breaking Through for COPD - Medscape
Dec 10, 2024 · T2 inflammation is “an inflammatory cascade led by IL-4, IL-13, and IL-5,” Mona Bafadhel, MD, chair of Respiratory Medicine at King’s College London, London, England, said in her ...
Topical JAK inhibitor Provides Sustained Control of HS - Medscape
Oct 3, 2024 · The proportion of patients reaching an AN90 or AN100 response, meaning clear or almost clear, were 19% and 38.5%, in continuous treatment and crossover arms, respectively.
8 New GI Studies With Practice-Shifting Implications - Medscape
Nov 12, 2024 · Whereas the RESPONSE trial removed decompensated patients, the ongoing phase 3 ASSURE trial results presented at this year’s meeting [5] included patients with compensated cirrhosis ...